自体造血干细胞移植治疗弥漫大B细胞淋巴瘤临床分析  

Autologous Hematopoietic Stem Cell Transplantation for Patients with Diffuse Large B-cell Lymphoma: A Retrospective Study

作　　者：陆晓林[1] 李艳[1] 黄文荣[1] 郭玥潞[1] 赵小利[1] 卢柠[1] 朱海燕[1] 王全顺[1] 于力[1] 靖彧[1] 

机构地区：[1]中国人民解放军总医院血液科,北京100853

出　　处：《中国实验血液学杂志》2013年第3期617-622,共6页Journal of Experimental Hematology

基　　金：基金项目:2012FC-TSYS-2014

摘　　要：本研究探讨自体造血干细胞移植(autologous hematopoietic stem cell transplantation,auto-HSCT)治疗弥漫大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)疗效及预后影响因素。回顾性分析本院1996-2011年67例DLBCL患者行auto-HSCT临床资料,观察生存结果并分析预后影响因素。结果表明,随访时间截至2012年11月1日,移植后中位随访时间40(1-197)个月,3年总体生存(overall survival,OS)和无进展生存(progression-free surviv-al,PFS)分别为70.6%和66.4%,5年OS和PFS分别为70.6%和63.8%。移植相关死亡率(transplant-related mor-tality,TRM)为7.2%,1年和3年累计复发率分别为16.5%和23.7%。单因素分析显示,患者年龄和移植前疾病状态是DLBCL患者auto-HSCT后长期生存的显著影响因素。结论:auto-HSCT治疗弥漫大B细胞淋巴瘤安全有效,年轻、移植前肿瘤负荷低的患者预后更好。The purpose of this study was to investigate the efficacy of autologous hematopoietic stem cell transplantation （auto-HSCT） for patients with diffuse large B-cell lymphoma （ DLBCL）, and analyse the factors influencing prognosis. The clinical data of 67 patients with DLBCL received auto-HSCT from 1996 to 2011 and cumulative overall survival （OS）, progression-free survival （PFS）, transplant-related mortality （TRM）, and relapse rate were retrospectively analyzed. The results showed that the median follow-up time was 40 months after transplantation. Three-year cumulative OS and PFS were 70.6% and 66.4% respectively, 5-year cumulative OS and PFS were 70.6% and 63.8% respectively, and TRM was 7.2%. One-year and three-year cumulative relapse rate were 16.5% and 23.7% respectively. Univa- riate analysis revealed that the age and pre-transplant disease status were significantly associated with poor prognosis （P 〈 0.05 ）. It is concluded that auto-HSCT is a safe and effective therapeutic option for patients with DLBCL, especially for the young patients or patients with better remission.

关 键 词：淋巴瘤 弥漫大B细胞淋巴瘤 自体造血干细胞移植 

分 类 号：R733.1[医药卫生—肿瘤]